AIA
TERN

Alera Investment Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Alera Investment Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$90.6K Buy
10,868
+676
+7% +$5.56K 0.01% 287
2024
Q2 		$69.4K Buy
+10,192
New +$61.7K 0.01% 276

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alera Investment Advisors's TERN Position: Q3 2024 in Review

Alera Investment Advisors increased its Terns Pharmaceuticals (TERN) stake by 6.6% in Q3 2024, buying an estimated $5.56K and bringing the position to 10,868 shares worth $90.6K. The position accounts for 0.01% of the portfolio, ranked #287.

Alera Investment Advisors first reported a position in TERN in Q2 2024 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold TERN as of Q3 2024.

  • Alera Investment Advisors held 10,868 shares of Terns Pharmaceuticals worth $90.6K as of Q3 2024.
  • Alera Investment Advisors bought 676 Terns Pharmaceuticals shares in Q3 2024, an estimated $5.56K.
  • Terns Pharmaceuticals made up 0.01% of Alera Investment Advisors's portfolio in Q3 2024, its #287 holding.
  • Alera Investment Advisors first reported a position in Terns Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2024.

Based on Alera Investment Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.